BriaCell Therapeutics Corp.

NASDAQ:BCTX

$4.1 USD

-$0.94 (-18.65%)

Volume
880.98K
Average Volume
1.55M
Market Capitalization
$12.08M
P/E Ratio
-4.53
Dividend Yield
0.00%
Price Target
$
Year High
$7.87
Year Low
$0.35
Payout Ratio
$0.00
Current Ratio
$1.65

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Dr. William V. Williams M.D.
Industry Biotechnology
Sector Healthcare
Current Symbol BCTX
CUSIP 10778Y302
CIK 0001610820
Web https://www.briacell.com
Phone 604 921 1810
Currency USD
Employees 16
Country CA

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 1.65
Quick Ratio 1.65
Cash Ratio 1.16

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -1.30
Price / Cash Flow -0.59
Price / Book 18.58

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 1 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.29
Trailing P/E Ratio -4.53
PEG Ratio 0.03
P/E Growth 0.03
Net Income $-4.79M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 536.29%
Return on Assets -159.35%

Financials Score

AltmanZ Score -20.31
Piotroski Score 1.00
Working Capital 3.23M
Total Assets 10.41M
Ebit -29.98M
Market Cap 12.08M
Total Liabilities 6.7M

Poll Results

About BriaCell Therapeutics Corp. (NASDAQ:BCTX) Stock

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. ...

BriaCell Therapeutics Announces Pricing of Public Offering

2025-02-03 19:59:00

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be $3.05 million. The offering is expected to close on February 5, 2025, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

2025-02-03 16:45:00

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

2025-02-03 07:30:00

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS™.

BriaCell Announces Completion of 15:1 Share Consolidation

2025-01-27 18:42:00

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the “Effective Date”), the Company completed a share consolidation (the “Consolidation”) of the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

2024-12-17 16:05:00

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024.

Frequently Asked Questions

What is the current BriaCell Therapeutics Corp. (BCTX) stock price?

BriaCell Therapeutics Corp.(NASDAQ:BCTX) stock price is $4.1 in the last trading session. During the trading session, BCTX stock reached the peak price of $7.87 while $0.35 was the lowest point it dropped to. The percentage change in BCTX stock occurred in the recent session was --18.65% while the dollar amount for the price change in BCTX stock was -$-0.94.

BCTX's industry and sector of operation?

The NASDAQ listed BCTX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BCTX?

Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary
Dr. William V. Williams M.D. | Chief Executive Officer, President & Director
Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer
Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer

How many employees does BCTX have?

Number of BCTX employees currently stands at 16. BCTX operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.

Link for BCTX official website?

Official Website of BCTX is: https://www.briacell.com

How do I contact BCTX?

BCTX could be contacted at phone #604 921 1810 and can also be accessed through its website. BCTX operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.

How many shares of BCTX are traded daily?

The average number of BCTX shares traded daily for last 3 months was 1.55M.

What is the market cap of BCTX currently?

The market value of BCTX currently stands at $12.08M with its latest stock price at $4.1